Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for correction of anemia in lymphoid malignancies
2009-015767-14Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in anemia of inflammation (AI) and Malignant lymphoid neoplasm (2 arms), sponsored by CSL Vifor. Primary endpoint: Mean change in hemoglobin at weeks 4, 6, and 8. Started Feb 2010; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anemia of inflammation (AI)Malignant lymphoid neoplasm
Beyond the preview
Go deeper on 2009-015767-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015767-14.